In this guest blog post, Larry LaMotte, spokesperson for Patients for Biologics Safety & Access and Vice President of Public Policy at the Immune Deficiency Foundation, discusses the possibility of biosimilars helping increase access to vital medications for patients with chronic and life-threatening conditions.
FDA has approved a new dose of vilazodone (Viibryd, Actavis) for the treatment of Major Depressive Disorder (MDD) in adults.
Regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) appears to reduce the risk of colorectal cancer in most individuals, but a few individuals with rare genetic variants do not share this benefit, according to a study published in the March 17 issue of JAMA.
To address the burden of COPD on hospital expenditures, on October 1, 2014, the Centers for Medicare & Medicaid Services included COPD in its Hospital Readmissions Reductions Program. This inclusion resulted in reduced Medicare reimbursement for hospitals that demonstrate excessive 30-day COPD patient readmission rates.
FDA approved its first treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders).
The United States Drug Enforcement Administration (DEA) on March 18 issued a nationwide alert about the dangers of fentanyl and fentanyl analogues/compounds.
Premera Blue Cross and Lifewise Health Plan had websites offering protections for affected individuals ready to go the day they announced a breach of up to 11 million records of members, vendors and employees.
Lemtrada (alemtuzumab) received FDA approval on November 14, 2014, under fast track designation, for the treatment of patients with relapsing forms of MS.Due to the safety profile, alemtuzumab should generally be reserved for patients who have had an inadequate response to 2 or more drugs indicated for MS.
FDA has approved asenapine (Saphris, Actavis) for treatment of manic or mixed episodes of bipolar I disorder in pediatric patients, ages 10 to 17 years old.
Alirocumab (Praluent), a PCSK9 inhibitor, reduced low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy, according to a study published online in the New England Journal of Medicine.
A majority of Americans have compared prices before getting care and most want to do so, but access is still a barrier.
There is widespread overuse of psychiatric drugs by older Americans with Alzheimer’s disease or dementia who live at home or in assisted living facilities, according to a new General Accountability Office (GAO) report.
In patients with type 2 diabetes and recent acute coronary syndrome (ACS), dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin compared to placebo did not increase the risk of heart failure (HF) outcomes, according to data published in The Lancet.
Expanding blood pressure screenings to non-primary care settings can help identify more patients with high blood pressure and could contribute to better hypertension control and management, according to a Kaiser Permanente study published in The Journal of Clinical Hypertension.
FDA released new draft guidance designed to make it easier for generic manufacturers to introduce competition to 38 existing drug products, according to the agency’s Federal Register notice.
You’ve considered all the risks posed by the new HIPAA guidelines, but did you include streaming media?
Read what a panel of distinguished industry experts has to say about the increasingly difficult job of managing specialty pharmaceuticals.
Blue Cross Blue Shield of Massachusetts has taken big steps to curb the growing opioid addiction problem.
Many employers that offer generous health insurance packages are not looking forward to 2018, when the so-called Cadillac tax will impose a 40% penalty on high-cost health plans.
Mobile device health apps have the potential to transform healthcare, but their exploding use is also giving rise to new concerns about privacy and security.
Provisions of the Affordable Care Act will cost $142 billion less over the 2016–2025 period than originally estimated by government agencies, due to slower premium growth and changes in enrollment sources.
Health plans focused on communicating more effectively with their members got good news from the J.D. Power 2015 Member Health Plan Study, which showed a 17 point bump in satisfaction in the areas of information and communication.
Health plans struggling to rein in pharmacy costs are using mail service, disease management programs, financial incentives for generics, member cost sharing, and, increasingly, limited and closed formularies.
Health plans and providers play a critical role in maintaining U.S. vaccination rates and can help reverse the recent MMR vaccination-rate decline, a factor responsible for the recent re-emergence of measles.
The digital revolution of the Internet of Things (IoT) has advanced the fields of home automation, automotive, energy and manufacturing, and healthcare is next.
Executives of Medicare managed plans can benefit from knowing the challenges of the Medical Loss Ratio, a key cost control tool that went into effect last year.
A nationwide interoperability roadmap released by the U.S. Department of Health and Human Services in January outlines a set of critical actions healthcare players need to take between now and 2024 to get to a fax machine-free future.
Healthcare stakeholders are touting the benefits of transparency, but to see real change, we also need clarity.
FDA has warned that the smoking cessation drug varenicline (Chantix) can interact with alcohol, resulting in some patients experiencing increased intoxicating effects of alcohol, sometimes associated with aggressive behavior and/or amnesia.
FDA's approval of the “generic" biologic prescription version of cancer medicine Neupogen opens the door to a movement that could save the US healthcare system tens of billions of dollars a year, according to Forbes.